February 15, 2017
Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1
ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells
Poster Title: Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.
Poster Session Date/Time: February 24, 11:30AM – 1:00PM; 5:30PM-6:30PM
Presenting Author: Hestia ... Read more
February 2, 2017
Actionable mutation results from a single blood draw, 72 hour turnaround time
February 2, 2017, Boulder, CO….Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRAS, BRAF mutations; ... Read more
January 26, 2017
Study Results, Presented at MSACL, Advance Biodesix®/Bioyong Agreement
Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat® test in Greater China. The data were presented in a poster ... Read more
January 9, 2017
US $38M; Potential Expansion into Other Asia/Pacific Countries, Additional Liquid Biopsy Products
Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood ... Read more
December 13, 2016
VeriStrat® Test Shown To Have Clinical Utility in Predicting Overall Survival of Afatinib-Treated Patients With Lung Cancer
December 13, 2016, Boulder, Colorado… Two studies demonstrating the clinical utility of the VeriStrat® test in the management of patients with non-small cell lung cancer (NSCLC) were presented last week ... Read more
December 7, 2016
Biodesix won the award for “Innovative Company of the Year” last night at the 2016 IQ Awards and Innovation Summit presented by BizWest Media. The other finalists in the category were Fort Collins-based Madwire and n.io of Broomfield.
“We are really in the business of helping cancer ... Read more
November 15, 2016 “The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision to optimize benefit,” said Dr. Jeffrey Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU-Langone Medical Center in New York City.
November 12, 2016
Biodesix Presents Data from Two Studies at 2016 AMP Annual Meeting
Biodesix® is presenting two posters with results of separate genomics studies at the AMP 2016 Annual Meeting. In the first study, analysis of blood test results from non-small cell (NSCLC) lung cancer patients who tested EGFR ... Read more
November 8, 2016
Blood-Based Assays to Predict Response to Combination Checkpoint Blockade, High dose interleukin 2 (HDIL-2) in Melanoma
November 8, Boulder, Colorado…Three studies involving the development and validation of Biodesix’ blood-based proteomic tests, to aid in patient selection or predicting outcomes in the use of immunotherapies, will be presented this ... Read more
October 31, 2016 Based on published clinical data, Humana, Medical Mutual of Ohio and Preferred One independently determined and published policy stating that VeriStrat can be considered medically necessary for patients with advanced NSCLC.